Stonebridge Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Stonebridge Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-17	Closed	-$14K	–	698
2023 Q3	$14K	Hold	17	–	–	﹤0.01%	550
2023 Q2	$12.2K	Hold	17	–	–	﹤0.01%	587
2023 Q1	$14K	Buy	17 +5	+42%	+$3.77K	﹤0.01%	562
2022 Q4	$8.66K	Buy	12 +2	+20%	+$1.48K	﹤0.01%	621
2022 Q3	$7K	Hold	10	–	–	﹤0.01%	644
2022 Q2	$6K	Hold	10	–	–	﹤0.01%	693
2022 Q1	$7K	Sell	10 -2	-17%	-$1.26K	﹤0.01%	729
2021 Q4	$8K	Hold	12	–	–	﹤0.01%	679
2021 Q3	$7K	Buy	12 +2	+20%	+$1.24K	﹤0.01%	679
2021 Q2	$6K	Buy	10 +5	+100%	+$2.53K	﹤0.01%	692
2021 Q1	$2K	Buy	+5	New	+$2.43K	﹤0.01%	854

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Stonebridge Capital Advisors's REGN Position: Q4 2023 in Review

Stonebridge Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 17 shares — an estimated $14K sold.

Stonebridge Capital Advisors first reported a position in REGN in Q1 2021 and held it in 11 quarters. The position peaked at $14K in Q3 2023. 1,273 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

Stonebridge Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Stonebridge Capital Advisors sold 17 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $14K.
Stonebridge Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 11 quarters.
Stonebridge Capital Advisors's Regeneron Pharmaceuticals position peaked at $14K in Q3 2023.
1,273 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.